# Curcumin Synergistically Sensitizes Multidrug-Resistant Lung Cancer to Doxorubicin Through Ferroptosis-Associated Oxidative Stress

**Authors:** Wing-Hin Lee, Ching-Yee Loo, Poh Yen Khor, Charles Gnanaraj, Cai Ping Koh, Chean Ring Leong, Kamal Dua, Stewart Yeung, Kit-Leong Cheong

PMC · DOI: 10.3390/antiox15030288 · Antioxidants · 2026-02-26

## TL;DR

Curcumin helps make lung cancer cells more sensitive to doxorubicin by increasing oxidative stress and triggering cell death through a process called ferroptosis.

## Contribution

This study reveals that curcumin synergistically enhances doxorubicin's effect in drug-resistant lung cancer via ferroptosis-associated oxidative stress.

## Key findings

- Combining curcumin with doxorubicin increases mitochondrial dysfunction and caspase-3 activation in resistant lung cancer cells.
- High-dose curcumin and doxorubicin synergistically induce ROS, iron overload, and lipid peroxidation.
- Molecular docking confirms curcumin and doxorubicin bind to ferroptosis regulators, supporting their role in oxidative stress.

## Abstract

Excessive oxidative stress can cause irreversible cytotoxic damage to both healthy and cancer cells through the induction of reactive oxygen species (ROS) mediated lipid peroxidation. Ferroptosis has recently been shown to promote lipid peroxidation due to the over-accumulation of iron. Although cancer cells possess elevated antioxidant capacity to neutralize chemotherapy-induced oxidative stress, the co-delivery of polyphenol compounds such as curcumin (CUR) can overwhelm these defenses by elevating intracellular ROS levels to a toxic threshold, thereby increasing anticancer efficacy. In this study, we evaluated the potential of CUR to chemosensitize doxorubicin (DOX) towards the DOX-resistant lung cell line (H69AR). Our results demonstrated that the combination of DOX and CUR resulted in a concentration-dependent behavior, where low-dose concentrations exhibited antagonistic effects, while high-dose IC50-equivalent concentrations shifted towards synergism. The combination induced significantly greater mitochondrial dysfunction, ATP depletion, cytochrome C release, and caspase-3 activation. This also resulted in excessive ROS generation, intracellular iron overload, and lipid peroxidation, accompanied by a reduction in antioxidant enzymatic activities. Pretreatment with N-acetyl-L-cysteine (ROS inhibitor) and ferrostatin-1 (ferroptosis inhibitor) further supported the involvement of oxidative stress and ferroptosis in modulating apoptosis and DNA fragmentation. Molecular docking analyses supported the binding of CUR and DOX to key ferroptosis regulators. This study shows the potential of CUR to sensitize DOX-resistant cancer cells through ferroptosis-linked-oxidative stress targeting.

## Linked entities

- **Chemicals:** curcumin (PubChem CID 969516), doxorubicin (PubChem CID 31703), N-acetyl-L-cysteine (PubChem CID 12035), ferrostatin-1 (PubChem CID 4068248)
- **Diseases:** lung cancer (MONDO:0005138)

## Full-text entities

- **Genes:** CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}
- **Diseases:** cancer (MESH:D009369), iron (MESH:D000090463), Lung Cancer (MESH:D008175), mitochondrial dysfunction (MESH:D028361), cytotoxic (MESH:D064420)
- **Chemicals:** ROS (MESH:D017382), N-acetyl-L-cysteine (MESH:D000111), ATP (MESH:D000255), polyphenol (MESH:D059808), CUR (MESH:D003474), DOX (MESH:D004317), lipid (MESH:D008055), ferrostatin-1 (MESH:C573944), iron (MESH:D007501)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13023544/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13023544/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC13023544/full.md

---
Source: https://tomesphere.com/paper/PMC13023544